Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03), Zacks reports. The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. During the same quarter in the prior year, the company earned ($0.31) EPS.

Cellectis Stock Up 2.3 %

NASDAQ CLLS traded up $0.04 during trading hours on Tuesday, reaching $1.80. 185,677 shares of the company's stock traded hands, compared to its average volume of 48,472. Cellectis has a 52-week low of $1.75 and a 52-week high of $3.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The firm has a 50-day simple moving average of $2.09 and a 200 day simple moving average of $2.28. The firm has a market cap of $100.05 million, a PE ratio of -1.38 and a beta of 3.10.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of Cellectis in a research note on Tuesday. They set a "sell" rating on the stock. Barclays reduced their target price on Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Tuesday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.